Clinical trial NCT00790192 - References

Schizophrenia — Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.

Citation(s)

•   Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A
  Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychoph
•   Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG
  Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 20
•   Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD
  Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014 Apr;19(2):197-205. d

A Phase 3 Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Clinical Trial to Study the Efficacy and Safety of Two Doses of Lurasidone in Acutely Psychotic Subjects With Schizophrenia (PEARL 3)

Details for clinical trial NCT00790192